Bayer trumpets $1bn CRISPR deal with Mammoth Bio
pharmaphorum
JANUARY 10, 2022
Bayer has bolstered its cell and gene therapy platform by securing access to a CRISPR-based gene-editing platform developed by US biotech Mammoth Biosciences.
Gene Editing Genetic Disease Licensing Trials 
52 
4 Life Sciences Trends for 2023
XTalks
DECEMBER 29, 2022
In 2022 alone, the US regulator approved four new gene therapies, showing the high interest in getting these therapies to market. In 2023, a number of gene therapies are expected to get the FDA green light. Given their precise targeting, gene therapies have largely been focused on oncology indications followed by rare genetic diseases.
Advances in neuroscience drug discovery
Drug Discovery World
FEBRUARY 22, 2024
For example, it can take up to it three years to recruit enough participants for a dementia clinical trial. years it takes to complete an entire cancer clinical trial. The organisation also notes that only 1% of the people that can take part in dementia clinical trials actually do so. This compares to the 2.3
Let's personalize your content